Bringing together talented scientists, experienced leaders and innovative entrepreneurs.

Learn More

Developing and commercializing innovative drugs to treat cancer and orphan diseases and protect healthy tissues.

Learn More

Building a robust pipeline of oncology and orphan drugs focused in multiple indications.

Learn More

Developing powerful drugs to protect from radiation.

Learn More

       

Product Portfolio

Our proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines.

View Our Product Portfolio

Our most advanced product candidate is entolimod, which we are developing as a radiation countermeasure and as an immunotherapy for oncology and other indications.

Entolimod (CBLB502) Biodefense Entolimod (CBLB502) Oncology

Clinical Trials

We are aggressively pursuing development and commercialization of oncology drugs, orphan applications, and a radiation countermeasure.

Enrollment is open for our therapeutic clinical trials for various indications with oncology drug candidates in the pipeline.

Learn More about our Phase 1 oncology studies with entolimod (CBLB502)

Recent News

Read All News

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue